Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Tenaya Therapeutics ( (TNYA) ) has provided an update.
Tenaya Therapeutics has reported promising early data from the MyPEAK-1 clinical trial involving TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The initial findings indicate that TN-201 is well tolerated, with no major cardiac toxicities observed, and shows potential for stabilizing or improving clinical markers of HCM. The data highlights effective transduction into heart muscle cells and measurable increases in transgene RNA and protein levels over time. These results support further investigation and boost confidence in the potential of TN-201 as a therapeutic option for HCM, with additional data from higher dose cohorts expected in 2025.
More about Tenaya Therapeutics
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing potential therapies to address the genetic causes of heart disease. Its primary market focus is on gene therapies for cardiac conditions, such as MYBPC3-associated hypertrophic cardiomyopathy (HCM), utilizing adeno-associated viral vector (AAV) technology.
YTD Price Performance: -11.11%
Average Trading Volume: 3,233,954
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $228.2M
Learn more about TNYA stock on TipRanks’ Stock Analysis page.
